Moderately to severely active crohn's disease clinical trials

Other conditions

33 trials are recruiting, according to ClinicalTrials.gov.

Checked against the registry on 22 November 2026. Listing a trial here is not a recommendation; taking part is voluntary and each study team decides who is eligible.

Recruiting · Phase 2

A Study of SL-325 in Crohn's Disease Patients

Ages 18 Years to 80 Years · 20 sites · Shattuck Labs, Inc.

NCT07753850 on ClinicalTrials.gov

Not yet recruiting · Phase 1

An Open-label, DDI Study to Investigate the Effects of Duvakitug on the PK of Selected Cytochrome P450 Substrates

Ages 18 Years to 65 Years · 0 sites · Sanofi

NCT07923383 on ClinicalTrials.gov

Recruiting · Phase 4

Treatment of Chinese Adult Subjects With Moderate to Severe Crohn's Disease With Tabellvi®

Ages 18 Years to 70 Years · 7 sites · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

NCT07663526 on ClinicalTrials.gov

Recruiting · Phase 3

A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in Children With Moderately to Severely Active Crohn's Disease

Ages 2 Years to 17 Years · 19 sites · Hoffmann-La Roche

NCT07298421 on ClinicalTrials.gov

Recruiting · Phase 4

A Clinical Trial of Taibowei® Adalimumab Injection in the Treatment of Chinese Pediatric Patients With Moderately to Severely Active Crohn's Disease

Ages 6 Years to 17 Years · 1 site · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

NCT07564505 on ClinicalTrials.gov

Recruiting · Phase 2

Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis

Ages 18 Years to 75 Years · 66 sites · AbbVie

NCT07697456 on ClinicalTrials.gov

Not yet recruiting · Phase 2

A Phase II Study of H021 Enteric-coated Tablets for Moderately to Severely Active Crohn's Disease

Ages 18 Years to 75 Years · 24 sites · Jiangsu Carephar Pharmaceutical Co., Ltd.

NCT07677514 on ClinicalTrials.gov

Recruiting · Phase 3

A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease

Ages 18 Years to no maximum · 285 sites · Janssen Research & Development, LLC

NCT07577843 on ClinicalTrials.gov

Recruiting · Phase 2

A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease

Ages 18 Years to 80 Years · 69 sites · Eli Lilly and Company

NCT07483073 on ClinicalTrials.gov

Recruiting · Phase 2

A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease

Ages 18 Years to 80 Years · 69 sites · Eli Lilly and Company

NCT07483099 on ClinicalTrials.gov

Recruiting · Phase 3

A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

Ages 18 Years to no maximum · 162 sites · Janssen Research & Development, LLC

NCT07499232 on ClinicalTrials.gov

Recruiting · Phase 3

A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

Ages 16 Years to 80 Years · 152 sites · Sanofi

NCT07184944 on ClinicalTrials.gov

Recruiting · Phase 2 / Phase 3

A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

Ages 18 Years to no maximum · 382 sites · Janssen Research & Development, LLC

NCT07196722 on ClinicalTrials.gov

Recruiting · Phase 3

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

Ages 16 Years to 80 Years · 481 sites · Sanofi

NCT07184931 on ClinicalTrials.gov

Recruiting · Phase 2

Clinical Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-261 in Subjects With Moderate to Severe Active Crohn's Disease

Ages 18 Years to 75 Years · 20 sites · Biocad

NCT07078994 on ClinicalTrials.gov

Recruiting · Phase 3

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

Ages 18 Years to 70 Years · 183 sites · Eli Lilly and Company

NCT06937099 on ClinicalTrials.gov

Recruiting · Phase 2

A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)

Ages 18 Years to 75 Years · 16 sites · Takeda

NCT06764615 on ClinicalTrials.gov

Recruiting · Phase 3

A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

Ages 16 Years to 80 Years · 198 sites · Hoffmann-La Roche

NCT06819891 on ClinicalTrials.gov

Recruiting · Phase 4

A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting

Ages 18 Years to 80 Years · 78 sites · Takeda

NCT06581328 on ClinicalTrials.gov

Recruiting · Phase 3

A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

Ages 16 Years to 80 Years · 354 sites · Hoffmann-La Roche

NCT06819878 on ClinicalTrials.gov

Recruiting · Phase 1

Clinical Trial of TQH3906 Capsules for the Treatment of Adult Patients With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease

Ages 18 Years to 75 Years · 30 sites · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

NCT06754891 on ClinicalTrials.gov

Recruiting · Phase 3

A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease

Ages 2 Years to 17 Years · 29 sites · Takeda

NCT06100289 on ClinicalTrials.gov

Recruiting · Phase 3

A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease

Ages 18 Years to 65 Years · 112 sites · Takeda

NCT06227910 on ClinicalTrials.gov

Recruiting · Phase 2

Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease

Ages 18 Years to 75 Years · 149 sites · Abivax S.A.

NCT06456593 on ClinicalTrials.gov

Recruiting · Phase 2

A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

Ages 18 Years to 85 Years · 216 sites · Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)

NCT06226883 on ClinicalTrials.gov

Recruiting · Phase 3

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

Ages 16 Years to 80 Years · 438 sites · Merck Sharp & Dohme LLC

NCT06430801 on ClinicalTrials.gov

Recruiting · Phase 3

A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease

Ages 2 Years to 17 Years · 85 sites · Janssen Research & Development, LLC

NCT05923073 on ClinicalTrials.gov

Recruiting · Phase 2

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

Ages 18 Years to 75 Years · 195 sites · Takeda

NCT06233461 on ClinicalTrials.gov

Recruiting · Phase 3

A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease

Ages 2 Years to 17 Years · 79 sites · AbbVie

NCT05995353 on ClinicalTrials.gov

Recruiting · Phase 4

PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease

Ages 18 Years to no maximum · 23 sites · University of Calgary

NCT05928039 on ClinicalTrials.gov

Recruiting · Phase 3

A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Disease

Ages 18 Years to 80 Years · 33 sites · Takeda

NCT05837897 on ClinicalTrials.gov

Recruiting · Phase 3

A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)

Ages 2 Years to 17 Years · 80 sites · Takeda

NCT04779320 on ClinicalTrials.gov

More: Acne clinical trials · Alzheimer’s disease and related dementias clinical trials · Cannabis use disorder clinical trials · Chronic hives (chronic urticaria) clinical trials · COPD (chronic obstructive pulmonary disease) clinical trials · Depression clinical trials · Depression (major depressive disorder) clinical trials · Osteoporosis clinical trials · Rett syndrome clinical trials